Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials.[1][2][3] However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.[4]
Clinical data | |
---|---|
Trade names | Pimodivir |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
Chemical and physical data | |
Formula | C20H19F2N5O2 |
Molar mass | 399.402 g·mol−1 |
3D model (JSmol) |
|
| |
|